In vitro and in vivo effects of a cyclooxygenase-2 inhibitor nimesulide analog JCC76 in aromatase inhibitors-insensitive breast cancer cells

Journal of Steroid Biochemistry and Molecular Biology

Volumn 126, Issue 1-2, 2011, Pages 10-18

  Zhong, Bo ^a   Cai, Xiaohan ^a   Yi, Xin ^a   Zhou, Aimin ^a   Chen, Shiuan ^b   Su, Bin ^a  

^a CLEVELAND STATE UNIVERSITY   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Aromatase inhibitor; Breast cancer; COX 2 inhibitor; Nimesulide; Resistance

Indexed keywords

AROMATASE INHIBITOR; CYCLOHEXANECARBOXYLIC ACID [3 (2,5 DIMETHYLBENZYLOXY) 4 (METHANESULFONYLMETHYLAMINO)PHENYL]AMIDE; CYCLOOXYGENASE 2 INHIBITOR; JCC 76; NIMESULIDE; PROTEIN BAD; PROTEIN BCL 2; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CANCER RESISTANCE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; TUMOR VOLUME; UPREGULATION;

ANIMALS; APOPTOSIS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOHEXANECARBOXYLIC ACIDS; CYCLOOXYGENASE 2 INHIBITORS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES;

ANIMALIA; MUS MUSCULUS;

EID: 79958846284     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2011.03.018     Document Type: Article

References (42)

1. I.E. Smith, and M. Dowsett Aromatase inhibitors in breast cancer N. Engl. J. Med. 348 2003 2431 2442 (Pubitemid 36682823)
2. M. Dowsett, and A. Howell Breast cancer: aromatase inhibitors take on tamoxifen Nat. Med. 8 2002 1341 1344 (Pubitemid 36019409)
3. R.W. Brueggemeier, J.C. Hackett, and E.S. Diaz-Cruz Aromatase inhibitors in the treatment of breast cancer Endocr. Rev. 26 2005 331 345 (Pubitemid 40686647)
4. M. Dowsett, C. Harper-Wynne, I. Boeddinghaus, J. Salter, M. Hills, M. Dixon, S. Ebbs, G. Gui, N. Sacks, and I. Smith HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer Cancer Res. 61 2001 8452 8458 (Pubitemid 33131124)
5. D. Jelovac, G. Sabnis, B.J. Long, L. Macedo, O.G. Goloubeva, and A.M. Brodie Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole Cancer Res. 65 2005 5380 5389 (Pubitemid 40834290)
6. L.A. Martin, I. Farmer, S.R. Johnston, S. Ali, C. Marshall, and M. Dowsett Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation J. Biol. Chem. 278 2003 30458 30468 (Pubitemid 36994549)
7. G.J. Sabnis, D. Jelovac, B. Long, and A. Brodie The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation Cancer Res. 65 2005 3903 3910 (Pubitemid 40616372)
8. W. Yue, J.P. Wang, M.R. Conaway, Y. Li, and R.J. Santen Adaptive hypersensitivity following long-term estrogen deprivation: involvement of multiple signal pathways J. Steroid Biochem. Mol. Biol. 86 2003 265 274 (Pubitemid 37412565)
9. S.R. Johnston, J. Head, S. Pancholi, S. Detre, L.A. Martin, I.E. Smith, and M. Dowsett Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer Clin. Cancer Res. 9 2003 524S 532S (Pubitemid 36105797)
10. G. Sabnis, O. Goloubeva, D. Jelovac, A. Schayowitz, and A. Brodie Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens Clin. Cancer Res. 13 2007 2751 2757 (Pubitemid 46788044)
11. G. Sabnis, A. Schayowitz, O. Goloubeva, L. Macedo, and A. Brodie Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen Cancer Res. 69 2009 1416 1428
12. R.E. Harris, J. Beebe-Donk, and G.A. Alshafie Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors BMC Cancer 6 2006 27
13. R.E. Harris, R.T. Chlebowski, R.D. Jackson, D.J. Frid, J.L. Ascenseo, G. Anderson, A. Loar, R.J. Rodabough, E. White, and A. McTiernan Women's Health Initiative, Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative Cancer Res. 63 2003 6096 6101 (Pubitemid 37187516)
14. R.E. Harris, S. Kasbari, and W.B. Farrar Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer Oncol. Rep. 6 1999 71 73
15. R.E. Harris, K.K. Namboodiri, and W.B. Farrar Nonsteroidal antiinflammatory drugs and breast cancer Epidemiology 7 1996 203 205 (Pubitemid 26068056)
16. L.R. Howe, and A.J. Dannenberg COX-2 inhibitors for the prevention of breast cancer J. Mammary Gland Biol. Neoplasia 8 2003 31 43 (Pubitemid 38129949)
17. R.E. Harris, G.A. Alshafie, H. Abou-Issa, and K. Seibert Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor Cancer Res. 60 2000 2101 2103 (Pubitemid 30225166)
18. J Zhu, J.W. Huang, P.H. Tseng, Y.T. Yang, J. Fowble, C.W. Shiau, Y.J. Shaw, S.K. Kulp, and C.S. Chen From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors Cancer Res. 64 2004 4309 4318 (Pubitemid 38802438)
19. J. Zhu, X. Song, H.P. Lin, D.C. Young, S. Yan, V.E. Marquez, and C.S. Chen Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents J. Natl. Cancer Inst. 94 2002 1745 1757 (Pubitemid 36004351)
20. X. Song, H.P. Lin, A.J. Johnson, P.H. Tseng, Y.T. Yang, S.K. Kulp, and C.S. Chen Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells J. Natl. Cancer Inst. 94 2002 585 591 (Pubitemid 34498645)
21. T. Kawamori, S. Nakatsugi, T. Ohta, T. Sugimura, and K. Wakabayashi Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, against PhIP-induced mammary carcinogenesis Adv. Exp. Med. Biol. 507 2002 371 376 (Pubitemid 37330207)
22. S. Nakatsugi, T. Ohta, T. Kawamori, M. Mutoh, T. Tanigawa, K. Watanabe, S. Sugie, T. Sugimura, and K. Wakabayashi Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine (PhIP)-induced mammary gland carcinogenesis in rats Jpn. J. Cancer Res. 91 2000 886 892
23. B. Su, E.S. Diaz-Cruz, S. Landini, and R.W. Brueggemeier Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition J. Med. Chem. 49 2006 1413 1419 (Pubitemid 43271894)
24. B. Su, R. Tian, M.V. Darby, and R.W. Brueggemeier Novel sulfonanilide analogs decrease aromatase activity in breast cancer cells: synthesis, biological evaluation, and ligand-based pharmacophore identification J. Med. Chem. 51 2008 1126 1135 (Pubitemid 351480376)
25. B. Su, E.S. Diaz-Cruz, S. Landini, and R.W. Brueggemeier Suppression of aromatase in human breast cells by a cyclooxygenase-2 inhibitor and its analog involves multiple mechanisms independent of cyclooxygenase-2 inhibition Steroids 73 2008 104 111 (Pubitemid 350236301)
26. B. Chen, B. Su, and S. Chen A COX-2 inhibitor nimesulide analog selectively induces apoptosis in Her2 overexpressing breast cancer cells via cytochrome c dependent mechanisms Biochem. Pharmacol. 77 2009 1787 1794
27. M. Dowsett, L.A. Martin, I. Smith, and S. Johnston Mechanisms of resistance to aromatase inhibitors J. Steroid Biochem. Mol. Biol. 95 2005 167 172 (Pubitemid 41137307)
28. W. Yue, P. Fan, J. Wang, Y. Li, and R.J. Santen Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells J. Steroid Biochem. Mol. Biol. 106 2007 102 110 (Pubitemid 47362658)
29. S. Masri, S. Phung, X. Wang, X. Wu, Y.C. Yuan, L. Wagman, and S. Chen Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor Cancer Res. 68 2008 4910 4918
30. B Su, S. Landini, D.D. Davis, and R.W. Brueggemeier Synthesis and biological evaluation of selective aromatase expression regulators in breast cancer cells J. Med. Chem. 50 2007 1635 1644 (Pubitemid 46564383)
31. D.J. Zhou, D. Pompon, and S.A. Chen Stable expression of human aromatase complementary DNA in mammalian cells: a useful system for aromatase inhibitor screening Cancer Res. 50 1990 6949 6954 (Pubitemid 20361096)
32. C.W. Shiau, C.C. Yang, S.K. Kulp, K.F. Chen, C.S. Chen, J.W. Huang, and C.S. Chen Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma Cancer Res. 65 2005 1561 1569 (Pubitemid 40270186)
33. M. Dowsett Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer Endocr. Relat. Cancer 8 2001 191 195 (Pubitemid 32947641)
34. M. Dowsett, S. Johnston, L.A. Martin, J. Salter, M. Hills, S. Detre, M.C. Gutierrez, S.K. Mohsin, J. Shou, D.C. Allred, R. Schiff, C.K. Osborne, and I. Smith Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience Endocr. Relat. Cancer 12 Suppl. 1 2005 S113 117
35. G. Tian, J.P. Yu, H.S. Luo, B.P. Yu, H. Yue, J.Y. Li, and Q. Mei Effect of nimesulide on proliferation and apoptosis of human hepatoma SMMC-7721 cells World J. Gastroenterol. 8 2002 483 487 (Pubitemid 34692747)
36. T. Hida, K. Kozaki, H. Muramatsu, A. Masuda, S. Shimizu, T. Mitsudomi, T. Sugiura, M. Ogawa, and T. Takahashi Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines Clin. Cancer Res. 6 2000 2006 2011 (Pubitemid 30305099)
37. J.Y. Li, X.Z. Wang, F.L. Chen, J.P. Yu, and H.S. Luo Nimesulide inhibits proliferation via induction of apoptosis and cell cycle arrest in human gastric adenocarcinoma cell line World J. Gastroenterol. 9 2003 915 920
38. G. Eibl, H.A. Reber, M.N. Wente, and O.J. Hines The selective cyclooxygenase-2 inhibitor nimesulide induces apoptosis in pancreatic cancer cells independent of COX-2 Pancreas 26 2003 33 41 (Pubitemid 36020264)
39. B. Su, M.V. Darby, and R.W. Brueggemeier Synthesis and biological evaluation of novel sulfonanilide compounds as antiproliferative agents for breast cancer J. Comb. Chem. 10 2008 475 483
40. A. Siddiqa, L.M. Long, L. Li, R.A. Marciniak, and I. Kazhdan Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathways BMC Cancer 8 2008 129
41. M. Tuna, A. Chavez-Reyes, and A.M. Tari HER2/neu increases the expression of Wilms' Tumor 1 (WT1) protein to stimulate S-phase proliferation and inhibit apoptosis in breast cancer cells Oncogene 24 2005 1648 1652 (Pubitemid 40396095)
42. R. Kumar, M. Mandal, A. Lipton, H. Harvey, and C.B. Thompson Overexpression of HER2 modulates bcl-2, bcl-XL, and tamoxifen-induced apoptosis in human MCF-7 breast cancer cells Clin. Cancer Res. 2 1996 1215 1219 (Pubitemid 26238454)